Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses a chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. The company was founded in 1995 and is based in Watertown, Massachusetts.
ENTA Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Enanta Pharmaceuticals Inc. To summarize, we found that Enanta Pharmaceuticals Inc ranked in the 26th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Enanta Pharmaceuticals Inc ended up being:
The business' balance sheet suggests that 1% of the company's capital is sourced from debt; this is greater than merely 5.97% of the free cash flow producing stocks we're observing.
As a business, Enanta Pharmaceuticals Inc experienced a tax rate of about 33% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than 91.02% of stocks generating free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Enanta Pharmaceuticals Inc? See ICUI, WAT, ILMN, XRAY, and A.
Axsome reports positive data from Major Depressive Disorder study Axsome Therapeutics Inc. (AXSM) announced encouraging results from its GEMINI Phase 3 trial. It was a randomized, double-blind, placebo-controlled, multi-center, U.S. trial, and involved 327 adult patients with confirmed moderate to severe MDD. The data showed that AXS-05 was showed rapid...
Avisol Capital Partners on Seeking Alpha | September 21, 2020
Enanta Pharmaceuticals ([[ENTA]] +2.0%) has dosed the first patient in its Phase 1 trial of EDP-297, potent and targeted follow-on farnesoid X receptor agonist, for the treatment of non-alcoholic steatohepatitis ((NASH)).“In preclinical studies, EDP-297 demonstrated a compelling product profile, with a potency greater than that published on any FXR agonist in clinical...